Paragon Associates & Paragon Associates Ii Joint Venture Lumos Pharma, Inc. Transaction History

Paragon Associates & Paragon Associates Ii Joint Venture

  • $56.1 Million
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$7.36 - $11.36 $368,000 - $568,000
-50,000 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$9.75 - $13.44 $487,500 - $672,000
50,000 New
50,000 $500,000

Others Institutions Holding LUMO

# of Institutions
42
Shares Held
2.29M
Call Options Held
0
Put Options Held
0
View Full List

About LUMOS PHARMA, INC.

LUMO Quotes by TradingView
  • Ticker LUMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,396,070
  • Market Cap $18.6M
  • Description
  • Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...
More about LUMO
Track This Portfolio

Track Paragon Associates & Paragon Associates Ii Joint Venture Portfolio

Follow Paragon Associates & Paragon Associates Ii Joint Venture and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paragon Associates & Paragon Associates Ii Joint Venture, based on Form 13F filings with the SEC.

News

Stay updated on Paragon Associates & Paragon Associates Ii Joint Venture with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email